Buy Cerebrolysin peptide Online (1-20 ml Ampoules) | Fast Delivery (2025)

Buy Cerebrolysin peptide Online!

Cerebrolysin is a mix of enzymatically treated neuropeptides (20%) and amino acids (80%) derived from pig brains. Its constituents can include low molecular weight neuropeptides that are similar to fragments of natural neurotrophic factors (NTF), for example, ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), glial cells derived neurotrophic factor (GDNF), nerve growth factor (NGF), and insulin-like growth factor (IGF).

Cerebrolysin has been studied for potential use in a wide variety of neurodegenerative disorders, such as dementia including Alzheimer’s disease, stroke, and traumatic brain injury (TBI).

Cerebrolysin is available in different ampoule sizes: from 2ml to 20ml. We offer worldwide shipping!

What is Cerebrolysin Used For?

Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects. In some countries this “smart drug” is used in the complex treatment of cerebrovascular disorders:

• Strokes and stroke complications;
• Alzheimer’s disease and other types of dementia;
• Traumatic brain injuries;
• Spinal cord injuries;
• ADHD in children;
• Antidepressant-resistant depressions;
• Other brain diseases.

What are Cerebrolysin Benefits?

According to the manufacturer, Cerebrolysin is used in the complex treatment of acute and chronic disorders of the central nervous system (CNS). It supports endogenous repair and recovery processes after an injury or degenerative disease. It also helps to protect the brain against pathological events and cascades. Cerebrolysin mechanism of action resides in its ability to activate endogenous defense mechanisms (ESM), which include four main components: 1) Neurotrophic, 2) Neuroprotection, 3) Neuroplasticity, and 4) Neurogenesis.

As practice shows, repeated and long-term courses of treatment with Cerebrolysin peptide lead to an increase in the effectiveness of neuro-therapy, especially in relation to improved cognitive and behavioral functions.

In clinical practice, Cerebrolysin is known to reduce symptoms of depression, cognitive impairment, and autonomic disorders. It is said to relieve pain syndrome and enhance the effect of tricyclic antidepressants.

Is Cerebrolysin Safe to Take?

Cerebrolysin has an excellent safety record. Unless taken in large amounts (>10 ml), adverse reactions are mild and rare.

Special attention shall be taken when stacking Cerebrolysin with antidepressants, including MAO inhibitors.

Where To Buy Cerebrolysin?

Authentic Cerebrolysin ampoules for injection are available at CosmicNootropic. We offer the most popular forms: Cerebrolysin 5ml and Cerebrolysin 10ml ampoules as well as other volumes depending on the purpose of use.

You do not need a prescription to obtain Cerebrolysin online. Buy it with worldwide delivery. CosmicNootropic offers bulk discounts 👍

What is the Optimal Cerebrolysin Dosage?

Cerebrolysin has indication-specific dosing. The most common regime for improving brain function is IM injections of 5 ml daily.The course of treatment is 4 weeks unless otherwise prescribed by your attending physician.

Dose recommendations from the manufacturer:

How to Inject Cerebrolysin?

The main ways of administering the drug are intramuscular (IM) and intravenous (IV). The gluteal region is the best spot to inject IM. Relax your muscle and inject slowly. Here are a couple of tips on how to make injections. Please follow the sterility instructions!

What are Cerebrolysin Side Effects?

Rare cases of adverse reactions to Cerebrolysin may include fatigue, headaches, dizziness, insomnia, etc.

Please note that it is important to follow the recommendations of the drug administration to minimize the chance of adverse reactions.

The drug is injected slowly. If the injection is made too fast, in rare cases, there can be a feeling of heat, sweating, dizziness, heart palpitations, or arrhythmia.

Cerebrolysin is reported to lose its effectiveness when used for longer than necessary. However, there are anecdotal cases of Cerebrolysin causing anxiety, headaches, and aches in the body when the medication brings no benefit any longer.

CEREBROLYSIN OFFICIAL INSTRUCTION

1. Rutheret al (1994) Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with Senile Dementia of the Alzheimer Type (SDAT) https://www.ncbi.nlm.nih.gov/pubmed/8159781
2. L. Francis-Turner, V. Valouskova (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study https://www.ncbi.nlm.nih.gov/pubmed/8848264
3. Schwab et al (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats – protective effects of Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/9085071
4. V. Valouskova and A. Gschanes (1999) Effects of NGF, b-FGF, and Cerebrolysin on Water Maze Performance and on Motor Activity of Rats: Short- and Long-Term Study https://www.ncbi.nlm.nih.gov/pubmed/10082636
5. Masliah et al (1999) Cerebrolysin Ameliorates Performance Deficits, and Neuronal Damage in Apolipoprotein E-Deficient Mice https://www.ncbi.nlm.nih.gov/pubmed/9972690
6. Bae et al (2000) A Double-Blind, Placebo-Controlled, Multicenter Study of Cerebrolysin for Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/11129744
7. Ruther et al (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy https://www.ncbi.nlm.nih.gov/pubmed/11005546
8. Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768
9. Hartbauer et al (2001) Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons https://www.ncbi.nlm.nih.gov/pubmed/11475013
10. Hartbauer et al (2001) Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons https://www.ncbi.nlm.nih.gov/pubmed/11459078
11. Eder et al (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats https://www.ncbi.nlm.nih.gov/pubmed/12197668
12. Panisset et al (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent https://www.ncbi.nlm.nih.gov/pubmed/12111446
13. Rockenstein et al (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance https://www.ncbi.nlm.nih.gov/pubmed/14628195
14. Ladurner et al (2004) Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial https://www.ncbi.nlm.nih.gov/pubmed/15583955
15. Alvarez et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/16420392
16. Rockenstein et al (2006) Cerebrolysin Decreases Amyloid-b Production by Regulating Amyloid Protein Precursor Maturation in a Transgenic Model of Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/16511867
17. Wei et al (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/17318304
18. Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393
19. Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537
20. Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059
21. Alvarez et al (2009) Reduced TNF-a and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/19531281
22. Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118
23. Guekht et al (2011) Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/20656516
24. Alcantara-Gonzalez et al (2012) Combined Administration of Cerebrolysin and Donepezil Induces Plastic Changes in Prefrontal Cortex in Aged Mice https://www.ncbi.nlm.nih.gov/pubmed/22826038
25. Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884
26. Menon et al (2012) Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals https://www.ncbi.nlm.nih.gov/pubmed/22229324
27. Chen et al (2013) Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study https://www.ncbi.nlm.nih.gov/pubmed/23656173
28. Amiri-Nikpour et al (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/25516711
29. Muresanu et al (2015) Cerebrolysin and Recovery After Stroke (CARS) A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/26564102
30. Ziganshina et al (2016) Cerebrolysin for acute ischaemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27918088
31. Chutko et al (2017) [The efficacy of cerebrolysin in the treatment of autism spectrum disorders] https://pubmed.ncbi.nlm.nih.gov/29053124/
32. M Brainin (2018) Cerebrolysin: a multi-target drug for recovery after stroke https://pubmed.ncbi.nlm.nih.gov/30004268/
33. Torshin et al (2019) [Cerebrolysin peptides as mood stabilizers] https://pubmed.ncbi.nlm.nih.gov/31994517/
34. Alzoubi et al (2020) Cerebrolysin prevents sleep deprivation induced memory impairment and oxidative stress https://pubmed.ncbi.nlm.nih.gov/31987894/
35. S Gavrilova, A Alvarez (2021) Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use https://pubmed.ncbi.nlm.nih.gov/32808294/
36. Strilciuc et al (2021) Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials https://pubmed.ncbi.nlm.nih.gov/34959697/
37. Mureșanu et al (2022) The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis https://pubmed.ncbi.nlm.nih.gov/35630065/
38. Villarreal-Reyna et al (2022) Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation https://pubmed.ncbi.nlm.nih.gov/36411485/